Longevity & Aging
resveratrol activates SIRT1
In plain terms: Does resveratrol switch on the longevity gene SIRT1?
Leans against Longevity & Aging 🔬 Includes disconfirming
Part of: 🧪 resveratrol
RefutedContestedStrong support
consensus score -0.44
Probably not — four independent labs showed the original finding was a lab-test quirk, only ever seen in the lab.
📅 Last reviewed: 2026-07-14 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
7 support 18 contradict 4 tested null 14 mixed · 43 sources, 25 independent groups
What the evidence shows
The origin claim (Howitz/Sinclair 2003). Decisively challenged as a Fluor-de-Lys fluorophore-substrate ASSAY ARTIFACT by four independent groups (Kaeberlein, Denu, Pfizer, GSK) - resveratrol is not a direct activator of SIRT1 with native substrates.
The evidence (50)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Dai H, Kustigian L, Carney D, Case A, Considine T, Hubbard BP, Perni RB, Riera TV, Szczepankiewicz B, Vlasuk GP, Stein RL 2010 · J Biol Chem | in-vitro | mixed | moderate | Kinetic/biophysical evidence for direct STAC-SIRT1 interaction; activation seen but substrate/fluorophore dependence acknowledged |
| Chung JH 2012 · Adipocyte | observational | contradicts | moderate | Review: resveratrol metabolic effects stem from PDE4 inhibition raising cAMP/AMPK; rolipram reproduces benefits, SIRT1 not the direct target |
| Niu ZL, Zhang L, Zhou YF, Wang ZA 2025 · Curr Protoc | in-vitro | tested-null | low | Nucleosome-substrate deacylation kinetics: native NCP platform for activator EC50 shows peptide assays overstate modulator potency vs chromatin |
| Manna D, Bhuyan R, Ghosh R 2018 · J Mol Model | mechanism | supports | low | Computational study models direct dihydropyridine/STAC binding driving SIRT1 conformational activation - mechanistic support for direct activation |
| Matysek A, Sun L, Kimmantudawage SP, Feng L, Maier AB 2023 · Ageing Res Rev | meta-analysis | contradicts | moderate | Systematic review of sirtuin-pathway compounds for dementia found sparse, inconsistent human evidence of SIRT1-attributable resveratrol/STAC benefit |
| Park SJ, Ahmad F, Philp A, Baar K, Williams T, Luo H, Ke H, Rehmann H, Taussig R, Brown AL, Kim MK, Beaven MA, Burgin AB, Manganiello V, Chung JH 2012 · Cell | animal | contradicts | high | Metabolic benefits arise from cAMP-PDE inhibition raising cAMP to activate Epac1/AMPK; SIRT1 activation is downstream/indirect, not direct |
| Milne JC, Lambert PD, Schenk S, Carney DP, Smith JJ, Gagne DJ, Jin L, Boss O, Perni RB, Vu CB, Bemis JE, Xie R, Disch JS, Ng PY, Nunes JJ, Lynch AV, Yang H, Galonek H, Israelian K, Choy W, Iffland A, Lavu S, Medvedik O, Sinclair DA, Olefsky JM, Jirousek MR, Elliott PJ, Westphal CH 2007 · Nature | in-vitro | mixed | high | Sirtris STACs 1000x more potent than resveratrol bind allosteric N-terminal site, lower Km for acetylated substrate; activation allosteric/substrate-linked |
| Hubbard BP, Gomes AP, Dai H, Li J, Case AW, Considine T, Riera TV, Lee JE, E SY, Lamming DW, Pentelute BL, Schuman ER, Stevens LA, Ling AJ, Armour SM, Michan S, Zhao H, Jiang Y, Sweitzer SM, Blum CA, Disch JS, Ng PY, Howitz KT, Rolo AP, Hamuro Y, Moss J, Perni RB, Ellis JL, Vlasuk GP, Sinclair DA 2013 · Science | in-vitro | contradicts | high | Identifies SIRT1 Glu230 allosteric site; STACs activate SIRT1 with specific hydrophobic substrate motifs (e.g. PGC-1a) - not pure assay artifact |
| Price NL, Gomes AP, Ling AJ, Duarte FV, Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro JS, Hubbard BP, Varela AT, Davis JG, Varamini B, Hafner A, Moaddel R, Rolo AP, Coppari R, Palmeira CM, de Cabo R, Baur JA, Sinclair DA 2012 · Cell Metab | animal | mixed | high | Inducible SIRT1-KO mice + cells. Aim: 'testing whether the ability of resveratrol to activate AMPK and increase mitochondrial function requires SIRT1 in vivo'. Moderate-dose effects were SIRT1-dependent ('SIRT1 is necessary for moderate doses of resveratrol to activate AMPK and increase NAD + and that SIRT1 acts upstream of AMPK'); high dose activated AMPK SIRT1-independently. No native-substrate enzymology: cannot separate direct from indirect SIRT1 activation, the claim's scope. Off-scope. |
| Liu F, Pang N, Xu RM, Yang N 2023 · Protein Cell | in-vitro | mixed | moderate | Review: SIRT1 activation by STACs is real but N-terminal-domain allosteric and substrate-sequence dependent, not universal direct activation |
| Brenner C 2022 · Life Metab | mechanism | contradicts | moderate | Argues original yeast Sir2 longevity/STAC framing was artifact-driven; rejects sirtuins as conserved longevity genes behind resveratrol-SIRT1 story |
| Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL, Scherer B, Sinclair DA 2003 · Nature | in-vitro | supports | moderate | Origin claim: resveratrol lowers SIRT1 Km, stimulates p53 deacetylation, extends yeast lifespan 70% |
| Scisciola L, Sarno F, Carafa V, Cosconati S, Di Maro S, Ciuffreda L, De Angelis A, Stiuso P, Feoli A, Sbardella G, Altucci L, Nebbioso A 2020 · Epigenetics | in-vitro | tested-null | low | Novel non-fluorophore SIRT1 activators (SCIC2) enhance deacetylase activity on native targets; frames resveratrol effect as scaffold-limited |
| Cai H, Scott E, Kholghi A, Andreadi C, Rufini A, Karmokar A, Britton RG, Horner-Glister E, Greaves P, Jawad D, James M, Howells L, Ognibene T, Malfatti M, Goldring C, Kitteringham N, Walsh J, Viskaduraki M, West K, Miller A, Hemingway D, Steward WP, Gescher AJ, Brown K 2015 · Sci Transl Med | animal | contradicts | high | Low dietary-dose resveratrol beat 200x higher dose via AMPK/mTOR/autophagy not dose-escalating SIRT1; non-linear PK argues against simple direct activation |
| Manjula R, Anuja K, Alcain FJ 2020 · Front Pharmacol | observational | mixed | low | Review: resveratrol SIRT1 activation is allosteric and conformation-dependent, effective only for select substrates |
| Fiorentino F, Fabbrizi E, Mai A, Rotili D 2025 · Med Res Rev | observational | mixed | moderate | Review concludes resveratrol is a genuine but weak, substrate-selective SIRT1 activator - reconciles artifact critique with allosteric evidence |
| Li X, Lee YJ, Jin F, Park YN, Deng Y, Kang Y, Yang JH, Chang JH, Kim DY, Kim JA, Chang YC, Ko HJ, Kim CH, Murakami M, Chang HW 2017 · Sci Rep | animal | mixed | moderate | Resveratrol suppressed anaphylaxis via SIRT1-downstream AMPK axis; framed as SIRT1 working through AMPK rather than direct enzymatic activation |
| Malospirito CC, Jara GE, Antunes VU, Elias GB, Dias MMG, Batista FAH, de Oliveira PSL, Figueira ACM 2025 · Proteins | mechanism | tested-null | low | Models SIRT1 N-terminal 3-helix bundle as substrate-anchoring interface; supports allosteric NTD activation but substrate-anchoring-dependent |
| Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, Brenner DE, Steward WP, Gescher AJ, Brown K 2010 · Cancer Res | observational | contradicts | moderate | Clinical PK: colorectal tissue reaches 674 nmol/g but plasma parent compound low, dominated by conjugates, limiting systemic direct SIRT1 engagement |
| Cao D, Wang M, Qiu X, Liu D, Jiang H, Yang N, Xu RM 2015 · Genes Dev | in-vitro | contradicts | high | Crystal structure: three resveratrol molecules mediate SIRT1 N-terminal binding to a coumarin peptide - structural basis for substrate-dependent activation |
| Orlandi, Stamerra, Strippoli, Vai 2017 · Redox Biol | in-vitro | supports | moderate | In yeast, RSV enhances Sir2-mediated deacetylation of the native substrate Pck1 (Sir2 protein unchanged, sir2-delta cells unresponsive, NAM reverses it); the short-lived phenotype follows because Sir2 is a NEGATIVE regulator of CLS. H4K16ac unchanged, so activation is substrate-selective; orthologue not SIRT1, and directness untested |
| Bursch KL, Goetz CJ, Smith BC 2024 · Molecules | mechanism | mixed | moderate | Narrative review: 'Instead of being comprehensive, this review discusses the well-characterized sirtuin activators and inhibitors available to date'. No own assays. Review — zero weight. |
| You W, Zheng W, Weiss S, Chua KF, Steegborn C 2019 · Sci Rep | in-vitro | mixed | moderate | Crystal structures show quercetin allosterically activates SIRT6 via a defined pocket; structural precedent for polyphenol allosteric activation |
| Nguyen GT, Gertz M, Steegborn C 2013 · Chem Biol | in-vitro | mixed | moderate | Crystal structures show 4'-bromo-resveratrol binds two SIRT3 sites; supports an allosteric site model relevant to SIRT1 activation |
| Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA 2006 · Nature | animal | mixed | high | Resveratrol shifts high-cal-diet mice toward healthy phenotype with raised AMPK/PGC-1a and SIRT1-pathway changes; consistent with but not direct activation |
| Kaeberlein M, McDonagh T, Heltweg B, Hixon J, Westman EA, Caldwell SD, Napper A, Curtis R, DiStefano PS, Fields S, Bedalov A, Kennedy BK 2005 · J Biol Chem | in-vitro | contradicts | high | Resveratrol activates Sir2/SIRT1 only on Fluor-de-Lys fluorophore-tagged peptides; no in-vivo Sir2 effect in 3 yeast backgrounds |
| Cuyàs E, Verdura S, Llorach-Parés L, Fernández-Arroyo S, Joven J, Martin-Castillo B, Bosch-Barrera J, Brunet J, Nonell-Canals A, Sanchez-Martinez M, Menendez JA 2018 · Front Endocrinol | mechanism | mixed | low | Computational+experimental: metformin docks SIRT1 N-terminal autoinhibitory region as direct STAC; supports allosteric-site model, non-resveratrol |
| Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S 2012 · Cell Metab | RCT | contradicts | high | 12wk 75mg/d resveratrol in non-obese women: no metabolic benefit, no change in putative targets AMPK, SIRT1, NAMPT or PGC-1a in muscle or adipose |
| Chen H, Wang Y, Gao Z, Yang W, Gao J 2019 · J Comput Aided Mol Des | mechanism | mixed | moderate | MD/MM-GBSA of 3-resveratrol SIRT1 complex: two stabilize substrate binding, third weakly bound; supports substrate-bridging not direct activation |
| Borra MT, Smith BC, Denu JM 2005 · J Biol Chem | in-vitro | contradicts | high | Borra: ~8x activation only with covalently-attached fluorophore - the artifact source |
| Hou X, Rooklin D, Fang H, Zhang Y 2016 · Sci Rep | mechanism | mixed | moderate | MD + fragment mapping: resveratrol is a substrate-specific interaction stabilizer at N-terminal domain, activating only loose-binding substrates |
| Beher D, Wu J, Cumine S, Kim KW, Lu SC, Atangan L, Wang M 2009 · Chem Biol Drug Des | in-vitro | contradicts | high | Beher: Fluor-de-Lys artificial substrate, no activation on p53 peptide |
| Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MKC, Kunz I, Schrauwen-Hinderling VB, Blaak E, Auwerx J, Schrauwen P 2011 · Cell Metab | RCT | mixed | high | 30d resveratrol in obese men raised muscle SIRT1/PGC-1a protein and AMPK with CR-like effects; markers up but cannot show direct enzyme activation |
| Liu F, Yang N 2020 · Phys Chem Chem Phys | mechanism | mixed | moderate | Multiscale free-energy model: FdL fluorophore and native hydrophobic residues only weakly correlated in driving SIRT1 activation by resveratrol |
| Ma S, Feng J, Zhang R, Chen J, Han D, Li X, Yang B, Li X, Fan M, Li C, Tian Z, Wang Y, Cao F 2017 · Oxid Med Cell Longev | animal | supports | moderate | Resveratrol alleviated diabetic cardiomyopathy via SIRT1-mediated mitochondrial regulation; no SIRT1-loss control to prove direct mechanism |
| Goh KP, Lee HY, Lau DP, Supaat W, Chan YH, Koh AF 2014 · Int J Sport Nutr Exerc Metab | RCT | supports | moderate | Resveratrol in T2DM raised skeletal-muscle SIRT1 expression and AMPK; expression rise attributed to SIRT1 but not direct enzyme activation |
| Gertz M, Nguyen GT, Fischer F, Suenkel B, Schlicker C, Fränzel B, Tomaschewski J, Aladini F, Becker C, Wolters D, Steegborn C 2012 · PLoS One | in-vitro | supports | moderate | Resveratrol directly modulates sirtuins (activates SIRT1/SIRT5, inhibits SIRT3) via a fluorophore-dependent mechanism - effect is substrate-conditional |
| Curry AM, White DS, Donu D, Cen Y 2021 · Front Physiol | observational | contradicts | moderate | Review: resveratrol direct SIRT1 activation confounded by fluorophore assays; few STACs reached clinic, underscoring weak direct-activation case |
| Pacholec M, Bleasdale JE, Chrunyk B, Cunningham D, Flynn D, Garofalo RS, Griffith D, Griffor M, Loulakis P, Pabst B, Qiu X, Stockman B, Thanabal V, Varghese A, Ward J, Withka J, Ahn K 2010 · J Biol Chem | in-vitro | contradicts | high | Pacholec: resveratrol+SRT1720 fail to activate SIRT1 with native substrate |
| Baksi A, Kraydashenko O, Zalevkaya A, Stets R, Elliott P, Haddad J, Hoffmann E, Vlasuk GP, Jacobson EW 2014 · Br J Clin Pharmacol | RCT | contradicts | moderate | Phase II SRT2104 (selective SIRT1 activator) in T2DM gave no significant glycaemic improvement; clinical SIRT1-activation translation underwhelming |
| Pezzuto JM 2019 · Biomol Ther | mechanism | contradicts | moderate | Narrative review, no own data; re-describes others' biophysics: 'employing NMR, surface plasmon resonance, and isothermal calorimetry, a report appeared definitively illustrating that resveratrol does not lead to activation of SIRT1 with native peptide or full-length protein substrates (Pacholec et al., 2010).' Also: 'molecular targets are numerous and a dominant mechanism is elusive or nonexistent.' Review — zero weight; Pacholec 2010 should carry the vote. |
| Shao D, Yao C, Kim MH, Fry J, Cohen RA, Costello CE, Matsui R, Seta F, McComb ME, Bachschmid MM 2019 · Redox Biol | in-vitro | contradicts | high | RAMSSAY mass-spec assay with biotin-acetyl-p53 peptide: resveratrol, SRT1720, S17834 all failed to activate endogenous SIRT1 on native substrate |
| Nin V, Escande C, Chini CC, Giri S, Camacho-Pereira J, Matalonga J, Lou Z, Chini EN 2012 · J Biol Chem | in-vitro | contradicts | moderate | SIRT1 acutely activated in cells by AMPK/PKA-driven dissociation from inhibitor DBC1 without NAD+ change; endogenous activation is indirect |
| Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK 2004 · Drug Metab Dispos | in-vitro | contradicts | high | Oral resveratrol well absorbed but near-zero bioavailability (<5 ng/mL unchanged); free plasma far below in-vitro SIRT1-activating doses |
| Zhang M, Lu P, Terada T, Sui M, Furuta H, Iida K, Katayama Y, Lu Y, Okamoto K, Suzuki M, Asakura T, Shimizu K, Hakuno F, Takahashi SI, Shimada N, Yang J, Ishikawa T, Tatsuzaki J, Nagata K 2021 · Commun Biol | in-vitro | supports | moderate | Resveratrol is this paper's positive control. Native (non-fluorogenic) Ac-p53 by HPLC-MS: 'Deacetylation was completed at 37°C in 2 h in the presence of 10 μM KPMF-8 or 10 μM resveratrol, but was incomplete in the absence of a STAC molecule' (Supplementary Fig. 2c; no replicates or statistics stated for this assay). ITC: resveratrol binds SIRT1(183-510+GS+641-665) not NTD-less SIRT1(243-510), not the peptide; raises SIRT1–Ac-p53 affinity 1.4x (KD 55.0 → 38.8 μM at 0.2 mM) vs ~8x for KPMF-8. MCF-7 deacetylase +1.2x (n=4), abolished by SIRT1 siRNA — but that assay used '0.2 mM FdL substrate', the fluorophore-tagged substrate at the centre of the artefact controversy, and authors say 'further research is needed to determine whether this observed deacetylase activation was due to direct stimulation of SIRT1'. |
| Scribbans TD, Ma JK, Edgett BA, Vorobej KA, Mitchell AS, Zelt JG, Simpson CA, Quadrilatero J, Gurd BJ 2014 · Appl Physiol Nutr Metab | RCT | contradicts | moderate | Resveratrol with HIIT lowered training-induced PGC-1a/SIRT1/SOD2 gene expression vs placebo, blunting rather than activating the SIRT1 axis |
| Hoffmann E, Wald J, Lavu S, Roberts J, Beaumont C, Haddad J, Elliott P, Westphal C, Jacobson E 2013 · Br J Clin Pharmacol | RCT | mixed | moderate | First-in-class selective SIRT1 activator SRT2104 tolerable with defined PK; Sirtris built dedicated activators as resveratrol's direct action was unreliable |
| Minor RK, Baur JA, Gomes AP, Ward TM, Csiszar A, Mercken EM, Abdelmohsen K, Shin YK, Canto C, Scheibye-Knudsen M, Krawczyk M, Irusta PM, Martín-Montalvo A, Hubbard BP, Zhang Y, Lehrmann E, White AA, Price NL, Swindell WR, Pearson KJ, Becker KG, Bohr VA, Gorospe M, Egan JM, Talan MI, Auwerx J, Westphal CH, Ellis JL, Ungvari Z, Vlasuk GP, Elliott PJ, Sinclair DA, de Cabo R 2011 · Sci Rep | animal | tested-null | low | Synthetic SIRT1 activator SRT1720 extends obese-mouse lifespan; mito effects SIRT1/PGC-1a-dependent (conditional KO), a purpose-built target vs resveratrol |
| Dai H, Case AW, Riera TV, Considine T, Lee JE, Hamuro Y, Zhao H, Jiang Y, Sweitzer SM, Pietrak B, Schwartz B, Blum CA, Disch JS, Caldwell R, Szczepankiewicz B, Oalmann C, Yee Ng P, White BH, Casaubon R, Narayan R, Koppetsch K, Bourbonais F, Wu B, Wang J, Qian D, Jiang F, Mao C, Wang M, Hu E, Wu JC, Perni RB, Vlasuk GP, Ellis JL 2015 · Nat Commun | in-vitro | mixed | high | Crystal structure of mini-hSIRT1-STAC complex shows direct activator binding to the N-terminal domain - direct activation mechanism, not artifact |
| Beijers RJ, Gosker HR, Sanders KJ, de Theije C, Kelders M, Clarke G, Cryan JF, van den Borst B, Schols AM 2020 · Clin Nutr | RCT | contradicts | moderate | 4wk resveratrol in COPD did not improve muscle mitochondrial function or alter SIRT1-pathway/inflammatory gene expression vs placebo |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.